Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (29356)	11/5/1999 8:51:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Bob, Fast track (if you are talking about FDA approval) means that the FDA has 6 months (instead of 12 months) from NDA submission date to give a letter on approval (can be approvable, not approvable at this time, or rejection). AHP and PFE are bidding for WLA. LGND has deals with all three, but with AHP and PFE the focus is on second generation SERMs, while with WLA it's third generation SERMs. Thus, I suspect that AHP/WLA or PFE/WLA would be plusses for the deals with LGND. A AHP/PFE could cause some consolidation in the SERM programs (but AHP/PFE has not been mentioned as a real possibility)